Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maternal RSV F nanoparticle vaccine trial in third-trimester pregnant women
2016-002302-39Phase 3Completed
- Sponsor
- Novavax
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing RSV F nanoparticle vaccine with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint in infant subjects. Started Jul 2016; status: completed.
02
Drugs
RSV F vaccine + aluminum phosphate
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-002302-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002302-39.